Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002981 · ClinicalTrials.gov registry record · NA
PET Scan in Treating Patients With Metastatic Prostate Cancer
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 173
- Enrollment target
NCT00002981: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00002981 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 173 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002981, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 173 participants
- Enrollment target
Study Summary
RATIONALE: New imaging procedures, such as PET scan, may improve the ability to detect new or recurrent prostate cancer.
Interventions
- RADIATION fludeoxyglucose F 18
- PROCEDURE positron emission tomography
- RADIATION methionine C 11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 1997-01 |
| Est. Completion | 2023-06-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002981
The ClinicalTrials.gov registry entry for NCT00002981 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fludeoxyglucose F 18 is the first listed.
NCT00002981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002981 about?
NCT00002981 is a clinical study titled "PET Scan in Treating Patients With Metastatic Prostate Cancer". RATIONALE: New imaging procedures, such as PET scan, may improve the ability to detect new or recurrent prostate cancer.
What is the current status of trial NCT00002981?
This trial is currently completed. It is a NA study. The enrollment target is 173 participants. The study started on 1997-01. Estimated completion is 2023-06-12.
What interventions are being tested in trial NCT00002981?
The interventions under investigation include: fludeoxyglucose F 18 (RADIATION), positron emission tomography (PROCEDURE), methionine C 11 (RADIATION).
Who is sponsoring clinical trial NCT00002981?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.